Drug intelligence / Profile preview

FluCell

Development stage: Preclinical
Lead developer: Johnson & Johnson
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

FluCell is a cell-based influenza vaccine developed by Crucell, utilizing its proprietary PER.C6® technology. Initially, worldwide commercial rights for FluCell were licensed to Sanofi Pasteur in December 2003, with Crucell retaining marketing rights only in Japan. In July 2010, Sanofi Pasteur returned these worldwide commercial rights to Crucell as part of a restructured partnership. This allowed Crucell to regain full control of its influenza program, which it intended to develop further with its partner Adimmune.

Brand names: FluCell

Beyond the preview

Go deeper on FluCell.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FluCell.

Explore the full profile